| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 81 | 2026 | 524 | 13.970 |
Why?
|
| Immunotherapy | 70 | 2026 | 819 | 9.960 |
Why?
|
| Neoplasms | 72 | 2026 | 3334 | 7.860 |
Why?
|
| Tumor Microenvironment | 46 | 2025 | 617 | 6.670 |
Why?
|
| CD8-Positive T-Lymphocytes | 48 | 2025 | 696 | 6.360 |
Why?
|
| T-Lymphocytes | 64 | 2022 | 1327 | 6.300 |
Why?
|
| Lymphocyte Activation | 57 | 2024 | 822 | 4.290 |
Why?
|
| Signal Transduction | 50 | 2026 | 3620 | 3.550 |
Why?
|
| Dendritic Cells | 21 | 2024 | 552 | 3.510 |
Why?
|
| Skin Neoplasms | 24 | 2023 | 638 | 3.460 |
Why?
|
| Programmed Cell Death 1 Receptor | 23 | 2025 | 199 | 3.350 |
Why?
|
| Antigens, Neoplasm | 27 | 2018 | 361 | 2.780 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 13 | 2026 | 168 | 2.700 |
Why?
|
| B7-H1 Antigen | 19 | 2024 | 332 | 2.550 |
Why?
|
| T-Lymphocyte Subsets | 21 | 2017 | 291 | 2.540 |
Why?
|
| Mice | 127 | 2026 | 12698 | 2.530 |
Why?
|
| Gastrointestinal Microbiome | 9 | 2022 | 661 | 2.400 |
Why?
|
| Melanoma, Experimental | 12 | 2026 | 114 | 2.370 |
Why?
|
| Receptors, Antigen, T-Cell | 35 | 2014 | 446 | 2.370 |
Why?
|
| Clonal Anergy | 11 | 2013 | 32 | 2.330 |
Why?
|
| Animals | 158 | 2026 | 28894 | 2.300 |
Why?
|
| beta Catenin | 8 | 2019 | 267 | 2.250 |
Why?
|
| Immunity, Innate | 16 | 2016 | 481 | 2.210 |
Why?
|
| Cancer Vaccines | 20 | 2019 | 168 | 2.140 |
Why?
|
| Antineoplastic Agents, Immunological | 10 | 2025 | 237 | 2.110 |
Why?
|
| Interferon-gamma | 31 | 2026 | 479 | 2.070 |
Why?
|
| Antibodies, Monoclonal | 29 | 2023 | 1416 | 2.000 |
Why?
|
| Membrane Proteins | 10 | 2019 | 1285 | 1.880 |
Why?
|
| Humans | 217 | 2026 | 98080 | 1.810 |
Why?
|
| Antineoplastic Agents | 23 | 2023 | 2373 | 1.770 |
Why?
|
| Neoplasms, Experimental | 11 | 2020 | 261 | 1.720 |
Why?
|
| Interleukin-12 | 17 | 2026 | 110 | 1.640 |
Why?
|
| Interleukin-2 | 29 | 2017 | 246 | 1.590 |
Why?
|
| Tumor Escape | 8 | 2018 | 55 | 1.560 |
Why?
|
| Chemokine CXCL10 | 3 | 2022 | 25 | 1.550 |
Why?
|
| Mice, Knockout | 31 | 2026 | 2207 | 1.530 |
Why?
|
| Mice, Inbred C57BL | 42 | 2026 | 3598 | 1.530 |
Why?
|
| Cell Line, Tumor | 26 | 2026 | 2888 | 1.520 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 21 | 2026 | 2658 | 1.520 |
Why?
|
| Interferon Type I | 5 | 2015 | 170 | 1.470 |
Why?
|
| CD28 Antigens | 13 | 2013 | 94 | 1.460 |
Why?
|
| PTEN Phosphohydrolase | 5 | 2019 | 151 | 1.420 |
Why?
|
| Ipilimumab | 10 | 2023 | 68 | 1.400 |
Why?
|
| Antigens, CD | 24 | 2017 | 484 | 1.390 |
Why?
|
| Cytotoxicity, Immunologic | 20 | 2020 | 218 | 1.390 |
Why?
|
| T-Lymphocytes, Regulatory | 7 | 2013 | 358 | 1.350 |
Why?
|
| Drug Resistance, Neoplasm | 9 | 2025 | 665 | 1.320 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 2 | 2024 | 51 | 1.310 |
Why?
|
| Lymphocyte Subsets | 3 | 2026 | 71 | 1.300 |
Why?
|
| Early Growth Response Protein 2 | 3 | 2017 | 17 | 1.260 |
Why?
|
| B7-1 Antigen | 17 | 2009 | 75 | 1.250 |
Why?
|
| Cytokines | 20 | 2024 | 889 | 1.240 |
Why?
|
| Mice, Transgenic | 35 | 2020 | 1604 | 1.200 |
Why?
|
| Antigen-Presenting Cells | 17 | 2016 | 146 | 1.170 |
Why?
|
| Microbiota | 6 | 2022 | 467 | 1.140 |
Why?
|
| Cell Proliferation | 15 | 2020 | 1790 | 1.090 |
Why?
|
| T-Lymphocytes, Cytotoxic | 23 | 2007 | 321 | 1.080 |
Why?
|
| Mast-Cell Sarcoma | 11 | 2001 | 15 | 1.070 |
Why?
|
| Repressor Proteins | 2 | 2024 | 447 | 1.050 |
Why?
|
| Immune Tolerance | 10 | 2018 | 386 | 0.980 |
Why?
|
| Cross-Priming | 6 | 2018 | 59 | 0.960 |
Why?
|
| Receptors, Immunologic | 3 | 2026 | 142 | 0.950 |
Why?
|
| Antigens, Differentiation | 13 | 2009 | 125 | 0.930 |
Why?
|
| Immunotherapy, Adoptive | 4 | 2017 | 327 | 0.930 |
Why?
|
| Lectins, C-Type | 1 | 2026 | 74 | 0.930 |
Why?
|
| DNA-Binding Proteins | 12 | 2019 | 1255 | 0.900 |
Why?
|
| CTLA-4 Antigen | 19 | 2023 | 146 | 0.890 |
Why?
|
| Myeloid Cells | 2 | 2025 | 121 | 0.890 |
Why?
|
| CD4-Positive T-Lymphocytes | 11 | 2014 | 502 | 0.890 |
Why?
|
| Protein Kinase C-delta | 1 | 2025 | 29 | 0.890 |
Why?
|
| Interferons | 2 | 2016 | 114 | 0.880 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 1 | 2024 | 10 | 0.860 |
Why?
|
| Immunoconjugates | 9 | 2002 | 138 | 0.860 |
Why?
|
| ras Proteins | 4 | 2014 | 137 | 0.860 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 3 | 2024 | 17 | 0.850 |
Why?
|
| Gene Expression Profiling | 12 | 2020 | 1565 | 0.840 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 16 | 1998 | 150 | 0.830 |
Why?
|
| Homeostasis | 5 | 2012 | 474 | 0.830 |
Why?
|
| Antibodies, Monoclonal, Humanized | 13 | 2023 | 1099 | 0.820 |
Why?
|
| Adaptive Immunity | 7 | 2016 | 193 | 0.800 |
Why?
|
| Oximes | 3 | 2019 | 25 | 0.800 |
Why?
|
| Antigens, Surface | 7 | 2009 | 100 | 0.790 |
Why?
|
| Kidney Neoplasms | 7 | 2022 | 556 | 0.770 |
Why?
|
| Th1 Cells | 11 | 2007 | 173 | 0.750 |
Why?
|
| Sulfonamides | 4 | 2019 | 351 | 0.750 |
Why?
|
| Anti-Bacterial Agents | 3 | 2019 | 882 | 0.740 |
Why?
|
| Dermatitis | 1 | 2022 | 34 | 0.730 |
Why?
|
| Wilms Tumor | 1 | 2022 | 30 | 0.720 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 4 | 2024 | 220 | 0.710 |
Why?
|
| Bifidobacterium | 3 | 2016 | 21 | 0.700 |
Why?
|
| Germ-Line Mutation | 1 | 2025 | 402 | 0.690 |
Why?
|
| Hot Temperature | 1 | 2022 | 228 | 0.690 |
Why?
|
| Up-Regulation | 7 | 2013 | 743 | 0.690 |
Why?
|
| Neovascularization, Pathologic | 4 | 2014 | 356 | 0.660 |
Why?
|
| Interferon-beta | 5 | 2016 | 127 | 0.660 |
Why?
|
| Treatment Outcome | 31 | 2026 | 9711 | 0.650 |
Why?
|
| Adaptor Proteins, Signal Transducing | 7 | 2016 | 312 | 0.650 |
Why?
|
| Female | 82 | 2026 | 51536 | 0.650 |
Why?
|
| Farnesyltranstransferase | 2 | 2012 | 7 | 0.640 |
Why?
|
| Immunity, Cellular | 4 | 2022 | 187 | 0.630 |
Why?
|
| Diacylglycerol Kinase | 2 | 2012 | 5 | 0.630 |
Why?
|
| DNA Repair | 1 | 2022 | 363 | 0.630 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2020 | 12 | 0.620 |
Why?
|
| Cell Differentiation | 12 | 2014 | 1646 | 0.620 |
Why?
|
| Leukocytes, Mononuclear | 7 | 2026 | 213 | 0.620 |
Why?
|
| Apoptosis | 8 | 2018 | 1752 | 0.620 |
Why?
|
| p21-Activated Kinases | 1 | 2020 | 17 | 0.620 |
Why?
|
| Flow Cytometry | 15 | 2016 | 720 | 0.620 |
Why?
|
| Macrophages | 8 | 2024 | 643 | 0.610 |
Why?
|
| Genetic Heterogeneity | 1 | 2020 | 71 | 0.610 |
Why?
|
| Colitis | 1 | 2022 | 264 | 0.600 |
Why?
|
| Membrane Glycoproteins | 14 | 2009 | 446 | 0.600 |
Why?
|
| Psoriasis | 1 | 2022 | 262 | 0.600 |
Why?
|
| Mutation | 9 | 2020 | 4392 | 0.590 |
Why?
|
| Chemotaxis, Leukocyte | 2 | 2017 | 39 | 0.590 |
Why?
|
| Peptides | 12 | 2018 | 669 | 0.590 |
Why?
|
| Gene Expression | 7 | 2016 | 1320 | 0.580 |
Why?
|
| Neoplasm Metastasis | 19 | 2026 | 1089 | 0.580 |
Why?
|
| Angiogenesis Inhibitors | 5 | 2015 | 280 | 0.570 |
Why?
|
| Enzyme Inhibitors | 4 | 2014 | 642 | 0.570 |
Why?
|
| Graft Rejection | 12 | 2018 | 1186 | 0.560 |
Why?
|
| Killer Cells, Natural | 3 | 2016 | 297 | 0.560 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2018 | 21 | 0.550 |
Why?
|
| Mycoplasma | 3 | 2008 | 3 | 0.550 |
Why?
|
| Molecular Targeted Therapy | 4 | 2021 | 321 | 0.550 |
Why?
|
| Mycoplasma Infections | 3 | 2008 | 9 | 0.540 |
Why?
|
| Neoadjuvant Therapy | 2 | 2021 | 478 | 0.540 |
Why?
|
| Adult | 45 | 2026 | 29539 | 0.540 |
Why?
|
| Mice, Inbred DBA | 20 | 2005 | 146 | 0.540 |
Why?
|
| Gene Deletion | 3 | 2025 | 353 | 0.540 |
Why?
|
| Recombinant Proteins | 13 | 2026 | 993 | 0.530 |
Why?
|
| Immune Evasion | 1 | 2018 | 37 | 0.530 |
Why?
|
| Phosphorylation | 10 | 2018 | 1145 | 0.530 |
Why?
|
| Oncogenes | 1 | 2018 | 102 | 0.520 |
Why?
|
| DNA | 5 | 2022 | 1274 | 0.520 |
Why?
|
| Male | 64 | 2026 | 47076 | 0.520 |
Why?
|
| Adenoviridae | 7 | 2011 | 340 | 0.520 |
Why?
|
| Antineoplastic Agents, Alkylating | 3 | 2014 | 136 | 0.510 |
Why?
|
| Chemokines | 4 | 2013 | 79 | 0.500 |
Why?
|
| Middle Aged | 51 | 2026 | 29428 | 0.500 |
Why?
|
| Immunity | 6 | 2020 | 160 | 0.490 |
Why?
|
| Carcinoma, Renal Cell | 7 | 2006 | 384 | 0.490 |
Why?
|
| Thymus Gland | 3 | 2009 | 205 | 0.490 |
Why?
|
| Nucleotides, Cyclic | 2 | 2015 | 13 | 0.480 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2017 | 68 | 0.470 |
Why?
|
| Lymphopenia | 3 | 2012 | 31 | 0.470 |
Why?
|
| Cytoplasmic Granules | 2 | 2006 | 97 | 0.460 |
Why?
|
| Inflammasomes | 1 | 2016 | 38 | 0.460 |
Why?
|
| Receptor, Interferon alpha-beta | 2 | 2014 | 23 | 0.460 |
Why?
|
| Interleukin-4 | 9 | 2007 | 136 | 0.460 |
Why?
|
| Clone Cells | 16 | 2020 | 220 | 0.450 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2018 | 401 | 0.450 |
Why?
|
| Quinazolines | 2 | 2016 | 221 | 0.450 |
Why?
|
| Aged | 42 | 2026 | 21758 | 0.440 |
Why?
|
| Gene Expression Regulation | 9 | 2016 | 2023 | 0.440 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 3 | 2012 | 125 | 0.440 |
Why?
|
| Glucose | 3 | 2008 | 704 | 0.440 |
Why?
|
| Immunomodulation | 4 | 2020 | 64 | 0.440 |
Why?
|
| H-2 Antigens | 4 | 2003 | 58 | 0.430 |
Why?
|
| Biomarkers, Tumor | 14 | 2025 | 1764 | 0.420 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 7 | 2015 | 373 | 0.410 |
Why?
|
| Pancreatic Neoplasms | 1 | 2020 | 769 | 0.410 |
Why?
|
| Ascites | 3 | 2018 | 55 | 0.400 |
Why?
|
| Aged, 80 and over | 24 | 2021 | 7389 | 0.400 |
Why?
|
| RNA Processing, Post-Transcriptional | 2 | 2007 | 132 | 0.400 |
Why?
|
| Cell Movement | 7 | 2015 | 814 | 0.400 |
Why?
|
| Lymphoma, Follicular | 2 | 2023 | 73 | 0.400 |
Why?
|
| Neoplasm Proteins | 5 | 2009 | 551 | 0.390 |
Why?
|
| HLA-A2 Antigen | 5 | 2018 | 32 | 0.380 |
Why?
|
| Th2 Cells | 6 | 2007 | 152 | 0.380 |
Why?
|
| Tumor Cells, Cultured | 18 | 2009 | 1028 | 0.380 |
Why?
|
| Mitogen-Activated Protein Kinases | 3 | 2003 | 218 | 0.380 |
Why?
|
| Blotting, Western | 5 | 2015 | 780 | 0.380 |
Why?
|
| Benzodioxoles | 1 | 2012 | 15 | 0.380 |
Why?
|
| Cells, Cultured | 11 | 2014 | 2855 | 0.380 |
Why?
|
| Lymphocyte Depletion | 2 | 2014 | 103 | 0.380 |
Why?
|
| Phosphoproteins | 3 | 2010 | 264 | 0.370 |
Why?
|
| Down-Regulation | 4 | 2010 | 529 | 0.370 |
Why?
|
| Wnt Signaling Pathway | 3 | 2019 | 105 | 0.370 |
Why?
|
| src-Family Kinases | 1 | 2012 | 70 | 0.370 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 7 | 2021 | 889 | 0.370 |
Why?
|
| Genetic Engineering | 2 | 2016 | 102 | 0.370 |
Why?
|
| Quinolones | 3 | 2012 | 57 | 0.360 |
Why?
|
| Disease Models, Animal | 7 | 2019 | 2572 | 0.350 |
Why?
|
| Proto-Oncogene Proteins B-raf | 4 | 2021 | 169 | 0.350 |
Why?
|
| Coxsackie and Adenovirus Receptor-Like Membrane Protein | 4 | 2014 | 12 | 0.350 |
Why?
|
| Transfection | 11 | 2015 | 883 | 0.350 |
Why?
|
| Calcium | 7 | 2004 | 1196 | 0.340 |
Why?
|
| Immunologic Memory | 3 | 2017 | 188 | 0.340 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 4 | 2018 | 46 | 0.340 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2011 | 184 | 0.340 |
Why?
|
| Drug Administration Schedule | 7 | 2019 | 839 | 0.340 |
Why?
|
| Isoenzymes | 2 | 2009 | 272 | 0.330 |
Why?
|
| Phospholipase C gamma | 1 | 2010 | 15 | 0.330 |
Why?
|
| Combined Modality Therapy | 11 | 2022 | 1751 | 0.330 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2014 | 640 | 0.330 |
Why?
|
| CD3 Complex | 12 | 2007 | 137 | 0.330 |
Why?
|
| Protein Kinase C | 2 | 2009 | 267 | 0.320 |
Why?
|
| Italy | 9 | 2023 | 113 | 0.320 |
Why?
|
| Clinical Trials as Topic | 11 | 2019 | 1129 | 0.320 |
Why?
|
| Oncolytic Virotherapy | 2 | 2022 | 36 | 0.310 |
Why?
|
| Immunologic Factors | 4 | 2020 | 179 | 0.310 |
Why?
|
| Proto-Oncogene Proteins c-kit | 4 | 2015 | 80 | 0.310 |
Why?
|
| Serine Endopeptidases | 3 | 2006 | 154 | 0.310 |
Why?
|
| Indoles | 4 | 2016 | 334 | 0.310 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2009 | 212 | 0.310 |
Why?
|
| Dose-Response Relationship, Drug | 9 | 2020 | 1950 | 0.300 |
Why?
|
| Immunological Synapses | 1 | 2009 | 6 | 0.300 |
Why?
|
| Nuclear Proteins | 3 | 2004 | 750 | 0.300 |
Why?
|
| Dacarbazine | 2 | 2014 | 104 | 0.300 |
Why?
|
| CD8 Antigens | 4 | 2005 | 82 | 0.290 |
Why?
|
| In Vitro Techniques | 10 | 2012 | 945 | 0.290 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2009 | 44 | 0.290 |
Why?
|
| Red-Cell Aplasia, Pure | 1 | 2008 | 5 | 0.290 |
Why?
|
| B-Lymphocytes | 6 | 2018 | 727 | 0.290 |
Why?
|
| Base Sequence | 8 | 2013 | 2222 | 0.290 |
Why?
|
| CD40 Antigens | 3 | 2023 | 43 | 0.280 |
Why?
|
| Cell Cycle | 3 | 2009 | 518 | 0.280 |
Why?
|
| Adoptive Transfer | 9 | 2016 | 174 | 0.280 |
Why?
|
| Cytotoxicity Tests, Immunologic | 3 | 2006 | 43 | 0.280 |
Why?
|
| Lung Neoplasms | 7 | 2024 | 2457 | 0.280 |
Why?
|
| Neoplasm Transplantation | 10 | 2009 | 399 | 0.280 |
Why?
|
| Cytological Techniques | 2 | 2006 | 30 | 0.280 |
Why?
|
| Transduction, Genetic | 5 | 2013 | 161 | 0.280 |
Why?
|
| Intercellular Adhesion Molecule-1 | 3 | 2005 | 77 | 0.270 |
Why?
|
| Receptors, Virus | 4 | 2011 | 74 | 0.270 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2008 | 72 | 0.270 |
Why?
|
| Salvage Therapy | 2 | 2010 | 239 | 0.270 |
Why?
|
| Ciprofloxacin | 1 | 2008 | 24 | 0.270 |
Why?
|
| Neoplasm Staging | 8 | 2019 | 2080 | 0.260 |
Why?
|
| Proteins | 4 | 2008 | 804 | 0.260 |
Why?
|
| Cell Culture Techniques | 6 | 2008 | 196 | 0.260 |
Why?
|
| Mice, Inbred BALB C | 14 | 2016 | 1110 | 0.260 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2007 | 37 | 0.260 |
Why?
|
| Epitopes | 5 | 2022 | 258 | 0.260 |
Why?
|
| Sirolimus | 3 | 2018 | 182 | 0.260 |
Why?
|
| Trans-Activators | 2 | 2000 | 447 | 0.260 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 5 | 2010 | 977 | 0.260 |
Why?
|
| Pyrimidines | 3 | 2015 | 413 | 0.260 |
Why?
|
| Receptors, Death Domain | 1 | 2007 | 3 | 0.260 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2007 | 25 | 0.260 |
Why?
|
| Cell Division | 9 | 2013 | 689 | 0.250 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 3 | 2007 | 119 | 0.250 |
Why?
|
| Immunosuppressive Agents | 5 | 2010 | 1013 | 0.250 |
Why?
|
| Cyclosporine | 2 | 2020 | 241 | 0.250 |
Why?
|
| Nucleotidyltransferases | 3 | 2016 | 32 | 0.250 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2021 | 301 | 0.250 |
Why?
|
| Prognosis | 7 | 2021 | 4116 | 0.250 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2025 | 849 | 0.250 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2013 | 370 | 0.250 |
Why?
|
| Apoptosis Regulatory Proteins | 6 | 2010 | 201 | 0.240 |
Why?
|
| Antigen Presentation | 6 | 2013 | 234 | 0.240 |
Why?
|
| Blood Proteins | 2 | 2004 | 147 | 0.240 |
Why?
|
| Recombination, Genetic | 2 | 2007 | 423 | 0.240 |
Why?
|
| Ascitic Fluid | 1 | 2006 | 36 | 0.240 |
Why?
|
| Immunophenotyping | 6 | 2006 | 227 | 0.230 |
Why?
|
| Ligands | 6 | 2015 | 486 | 0.230 |
Why?
|
| Enzyme Activation | 4 | 2014 | 679 | 0.230 |
Why?
|
| Abatacept | 9 | 2002 | 89 | 0.230 |
Why?
|
| Uveal Neoplasms | 2 | 2016 | 12 | 0.230 |
Why?
|
| Carmustine | 1 | 2005 | 70 | 0.230 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2018 | 270 | 0.230 |
Why?
|
| Biomarkers | 4 | 2022 | 2020 | 0.230 |
Why?
|
| Immune System | 5 | 2018 | 106 | 0.230 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2005 | 117 | 0.230 |
Why?
|
| Cell Separation | 3 | 2016 | 200 | 0.230 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2016 | 1535 | 0.230 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2023 | 1173 | 0.230 |
Why?
|
| Radiosurgery | 2 | 2020 | 351 | 0.220 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 342 | 0.220 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2018 | 220 | 0.220 |
Why?
|
| Antibody Formation | 2 | 2022 | 172 | 0.220 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2024 | 10 | 0.220 |
Why?
|
| Tryptophan Oxygenase | 1 | 2004 | 10 | 0.220 |
Why?
|
| Protein Processing, Post-Translational | 3 | 2013 | 412 | 0.220 |
Why?
|
| Guanine | 1 | 2005 | 194 | 0.220 |
Why?
|
| Lymphoid Tissue | 1 | 2005 | 54 | 0.220 |
Why?
|
| Benzimidazoles | 2 | 2016 | 118 | 0.220 |
Why?
|
| Growth Inhibitors | 3 | 1989 | 41 | 0.220 |
Why?
|
| Time Factors | 8 | 2020 | 5567 | 0.210 |
Why?
|
| Disease Progression | 6 | 2018 | 1610 | 0.210 |
Why?
|
| 4-1BB Ligand | 1 | 2024 | 4 | 0.210 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2016 | 400 | 0.210 |
Why?
|
| Skin | 2 | 2019 | 591 | 0.210 |
Why?
|
| Lymph Nodes | 6 | 2022 | 560 | 0.210 |
Why?
|
| Pyrroles | 2 | 2004 | 165 | 0.210 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2004 | 82 | 0.210 |
Why?
|
| Genetic Vectors | 6 | 2007 | 426 | 0.200 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2003 | 68 | 0.200 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2016 | 1394 | 0.200 |
Why?
|
| Brain Neoplasms | 3 | 2019 | 839 | 0.200 |
Why?
|
| Opportunistic Infections | 1 | 2004 | 57 | 0.200 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 5 | 2010 | 114 | 0.200 |
Why?
|
| Antibodies, Neutralizing | 1 | 2024 | 174 | 0.200 |
Why?
|
| fas Receptor | 1 | 2003 | 73 | 0.200 |
Why?
|
| Immunization | 6 | 2006 | 154 | 0.200 |
Why?
|
| Lymphokines | 10 | 1995 | 74 | 0.200 |
Why?
|
| Interleukin-6 | 5 | 2020 | 282 | 0.190 |
Why?
|
| Luciferases | 3 | 2012 | 128 | 0.190 |
Why?
|
| Arthritis | 1 | 2023 | 49 | 0.190 |
Why?
|
| Extracellular Traps | 1 | 2022 | 17 | 0.190 |
Why?
|
| Promoter Regions, Genetic | 3 | 2012 | 977 | 0.190 |
Why?
|
| Benzamides | 2 | 2014 | 260 | 0.190 |
Why?
|
| Piperidines | 3 | 2019 | 172 | 0.190 |
Why?
|
| Mitochondria | 2 | 2025 | 650 | 0.190 |
Why?
|
| Research | 2 | 2016 | 257 | 0.190 |
Why?
|
| Congresses as Topic | 3 | 2012 | 123 | 0.190 |
Why?
|
| Cell Line | 7 | 2006 | 2483 | 0.190 |
Why?
|
| Molecular Sequence Data | 9 | 2012 | 2896 | 0.190 |
Why?
|
| Cytoskeleton | 1 | 2004 | 200 | 0.190 |
Why?
|
| Administration, Oral | 3 | 2017 | 674 | 0.180 |
Why?
|
| Transcription Factors | 2 | 2016 | 1717 | 0.180 |
Why?
|
| Vaccination | 2 | 2022 | 323 | 0.180 |
Why?
|
| Adrenal Insufficiency | 1 | 2022 | 23 | 0.180 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2022 | 33 | 0.180 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 59 | 0.180 |
Why?
|
| RNA, Messenger | 7 | 2011 | 2063 | 0.180 |
Why?
|
| Piperazines | 2 | 2014 | 306 | 0.180 |
Why?
|
| Drug Synergism | 4 | 2018 | 317 | 0.180 |
Why?
|
| Internationality | 2 | 2012 | 79 | 0.170 |
Why?
|
| Biological Specimen Banks | 1 | 2022 | 82 | 0.170 |
Why?
|
| Pandemics | 3 | 2022 | 916 | 0.170 |
Why?
|
| Mastocytoma | 1 | 2001 | 4 | 0.170 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2013 | 700 | 0.170 |
Why?
|
| Bone Marrow Cells | 4 | 2003 | 269 | 0.170 |
Why?
|
| Cell Nucleus | 1 | 2004 | 615 | 0.170 |
Why?
|
| RNA | 2 | 2022 | 595 | 0.170 |
Why?
|
| Oligopeptides | 2 | 2001 | 207 | 0.170 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2022 | 707 | 0.170 |
Why?
|
| src Homology Domains | 1 | 2001 | 46 | 0.170 |
Why?
|
| Biopsy | 4 | 2019 | 1224 | 0.170 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2001 | 47 | 0.170 |
Why?
|
| Carrier Proteins | 3 | 2016 | 667 | 0.170 |
Why?
|
| Autoimmune Diseases | 1 | 2023 | 259 | 0.160 |
Why?
|
| STAT1 Transcription Factor | 3 | 2011 | 60 | 0.160 |
Why?
|
| Neurilemmoma | 1 | 2021 | 39 | 0.160 |
Why?
|
| Actins | 1 | 2004 | 480 | 0.160 |
Why?
|
| Hematologic Neoplasms | 1 | 2004 | 383 | 0.160 |
Why?
|
| Transplantation Tolerance | 2 | 2018 | 145 | 0.160 |
Why?
|
| Models, Immunological | 2 | 2015 | 86 | 0.160 |
Why?
|
| Macrophage Activation | 2 | 2024 | 53 | 0.160 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2020 | 42 | 0.160 |
Why?
|
| HSP40 Heat-Shock Proteins | 2 | 2012 | 18 | 0.160 |
Why?
|
| Saliva | 1 | 2021 | 134 | 0.160 |
Why?
|
| Herpesvirus 1, Human | 1 | 2022 | 210 | 0.160 |
Why?
|
| Forkhead Transcription Factors | 2 | 2013 | 183 | 0.160 |
Why?
|
| Lymphocyte Culture Test, Mixed | 3 | 2013 | 73 | 0.160 |
Why?
|
| Government Agencies | 1 | 2020 | 13 | 0.160 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 338 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2020 | 108 | 0.150 |
Why?
|
| Thrombosis | 1 | 2022 | 318 | 0.150 |
Why?
|
| Fever | 1 | 2020 | 122 | 0.150 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2011 | 310 | 0.150 |
Why?
|
| C-Reactive Protein | 1 | 2020 | 208 | 0.150 |
Why?
|
| Young Adult | 6 | 2025 | 7507 | 0.150 |
Why?
|
| Polymyositis | 1 | 1999 | 8 | 0.150 |
Why?
|
| Biomedical Research | 2 | 2016 | 471 | 0.150 |
Why?
|
| Informed Consent | 1 | 2022 | 284 | 0.150 |
Why?
|
| Respiratory Muscles | 1 | 1999 | 27 | 0.150 |
Why?
|
| Societies, Medical | 3 | 2013 | 682 | 0.150 |
Why?
|
| MAP Kinase Kinase 4 | 2 | 2011 | 61 | 0.150 |
Why?
|
| Patient Care Planning | 1 | 2020 | 92 | 0.150 |
Why?
|
| Thymoma | 1 | 1999 | 33 | 0.150 |
Why?
|
| Octreotide | 1 | 1999 | 32 | 0.150 |
Why?
|
| Growth Substances | 2 | 1990 | 79 | 0.150 |
Why?
|
| Antifungal Agents | 1 | 2020 | 126 | 0.150 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2019 | 110 | 0.150 |
Why?
|
| CRISPR-Cas Systems | 1 | 2020 | 113 | 0.140 |
Why?
|
| Thymus Neoplasms | 1 | 1999 | 48 | 0.140 |
Why?
|
| Granzymes | 3 | 2006 | 96 | 0.140 |
Why?
|
| Protein-Tyrosine Kinases | 5 | 2004 | 304 | 0.140 |
Why?
|
| Genes, myc | 2 | 2018 | 38 | 0.140 |
Why?
|
| Diet | 1 | 2022 | 469 | 0.140 |
Why?
|
| Tumor Burden | 2 | 2017 | 333 | 0.140 |
Why?
|
| Interleukin-3 | 4 | 1994 | 39 | 0.140 |
Why?
|
| Azetidines | 2 | 2019 | 38 | 0.140 |
Why?
|
| Xanthones | 2 | 2015 | 10 | 0.140 |
Why?
|
| Gene Targeting | 2 | 2013 | 72 | 0.140 |
Why?
|
| Needs Assessment | 1 | 2020 | 174 | 0.140 |
Why?
|
| Antibody Affinity | 1 | 2018 | 38 | 0.140 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 1999 | 159 | 0.140 |
Why?
|
| Bifidobacterium longum | 1 | 2018 | 2 | 0.140 |
Why?
|
| Carcinogenesis | 1 | 2020 | 241 | 0.140 |
Why?
|
| CD4 Antigens | 7 | 2003 | 81 | 0.140 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2017 | 8 | 0.130 |
Why?
|
| Chemoradiotherapy | 1 | 2020 | 337 | 0.130 |
Why?
|
| Enterococcus faecium | 1 | 2018 | 33 | 0.130 |
Why?
|
| Advisory Committees | 3 | 2012 | 95 | 0.130 |
Why?
|
| Databases, Factual | 1 | 2022 | 1094 | 0.130 |
Why?
|
| Neuroblastoma | 1 | 2021 | 409 | 0.130 |
Why?
|
| Chemokine CXCL9 | 1 | 2017 | 8 | 0.130 |
Why?
|
| Integrin alpha Chains | 1 | 2017 | 21 | 0.130 |
Why?
|
| Analysis of Variance | 2 | 2012 | 889 | 0.130 |
Why?
|
| Liver | 3 | 2004 | 1231 | 0.130 |
Why?
|
| Deoxyglucose | 2 | 2008 | 40 | 0.130 |
Why?
|
| Polymerase Chain Reaction | 3 | 2015 | 895 | 0.130 |
Why?
|
| Fingolimod Hydrochloride | 1 | 2017 | 30 | 0.130 |
Why?
|
| SOX9 Transcription Factor | 1 | 2016 | 31 | 0.120 |
Why?
|
| Proto-Oncogenes | 1 | 2016 | 60 | 0.120 |
Why?
|
| HLA-A Antigens | 1 | 2016 | 39 | 0.120 |
Why?
|
| Lymphocytes | 2 | 2004 | 461 | 0.120 |
Why?
|
| Metformin | 1 | 2018 | 132 | 0.120 |
Why?
|
| Antibodies | 2 | 2015 | 348 | 0.120 |
Why?
|
| Extracellular Matrix | 1 | 2018 | 258 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2025 | 2558 | 0.120 |
Why?
|
| Drug Approval | 2 | 2020 | 69 | 0.120 |
Why?
|
| Protein Binding | 3 | 2022 | 1554 | 0.120 |
Why?
|
| Survival Analysis | 5 | 2021 | 1527 | 0.120 |
Why?
|
| Transcriptome | 2 | 2019 | 820 | 0.120 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2016 | 22 | 0.120 |
Why?
|
| Survival Rate | 7 | 2020 | 2041 | 0.120 |
Why?
|
| Caspase 1 | 1 | 2016 | 22 | 0.120 |
Why?
|
| Pyroptosis | 1 | 2016 | 6 | 0.120 |
Why?
|
| I-kappa B Kinase | 1 | 2016 | 42 | 0.120 |
Why?
|
| Mice, Nude | 3 | 2018 | 830 | 0.120 |
Why?
|
| Cytosol | 1 | 2016 | 193 | 0.120 |
Why?
|
| Anemia | 2 | 2009 | 135 | 0.120 |
Why?
|
| PPAR gamma | 1 | 2016 | 80 | 0.110 |
Why?
|
| Cohort Studies | 4 | 2021 | 3212 | 0.110 |
Why?
|
| Feces | 1 | 2018 | 387 | 0.110 |
Why?
|
| Immunotherapy, Active | 1 | 1995 | 15 | 0.110 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 568 | 0.110 |
Why?
|
| Lymphatic Vessels | 1 | 2016 | 74 | 0.110 |
Why?
|
| Receptors, CXCR3 | 1 | 2015 | 13 | 0.110 |
Why?
|
| DNA Damage | 1 | 2017 | 399 | 0.110 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2016 | 556 | 0.110 |
Why?
|
| DNA, Neoplasm | 1 | 2016 | 267 | 0.110 |
Why?
|
| Peptide Fragments | 2 | 2009 | 480 | 0.110 |
Why?
|
| Leukemia L1210 | 4 | 2000 | 12 | 0.110 |
Why?
|
| Maximum Tolerated Dose | 3 | 2019 | 265 | 0.110 |
Why?
|
| Gene Knockout Techniques | 1 | 2015 | 84 | 0.110 |
Why?
|
| Cluster Analysis | 1 | 2016 | 401 | 0.110 |
Why?
|
| Skin Transplantation | 1 | 2016 | 191 | 0.110 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2015 | 88 | 0.110 |
Why?
|
| Phenotype | 4 | 2017 | 2638 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 338 | 0.110 |
Why?
|
| Proto-Oncogene Proteins | 2 | 1995 | 682 | 0.110 |
Why?
|
| Wnt Proteins | 1 | 2015 | 128 | 0.110 |
Why?
|
| Complement System Proteins | 1 | 2015 | 87 | 0.110 |
Why?
|
| Symbiosis | 1 | 2015 | 130 | 0.100 |
Why?
|
| Adjuvants, Immunologic | 2 | 2001 | 176 | 0.100 |
Why?
|
| Stromal Cells | 2 | 2013 | 153 | 0.100 |
Why?
|
| Benzazepines | 1 | 2014 | 64 | 0.100 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2014 | 99 | 0.100 |
Why?
|
| Inositol Phosphates | 1 | 1994 | 16 | 0.100 |
Why?
|
| Interleukins | 6 | 2006 | 135 | 0.100 |
Why?
|
| Lymphatic Metastasis | 2 | 2016 | 520 | 0.100 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2014 | 146 | 0.100 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2016 | 336 | 0.100 |
Why?
|
| Child | 4 | 2022 | 7681 | 0.100 |
Why?
|
| Sunlight | 1 | 2013 | 27 | 0.100 |
Why?
|
| Gene Regulatory Networks | 1 | 2016 | 337 | 0.100 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 217 | 0.100 |
Why?
|
| Histocompatibility Antigens Class II | 3 | 2016 | 174 | 0.100 |
Why?
|
| Colony-Stimulating Factors | 2 | 1990 | 13 | 0.100 |
Why?
|
| Genes, RAG-1 | 2 | 2006 | 11 | 0.100 |
Why?
|
| Mucous Membrane | 1 | 2013 | 82 | 0.100 |
Why?
|
| Gene Amplification | 1 | 2013 | 142 | 0.090 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2013 | 557 | 0.090 |
Why?
|
| Positron-Emission Tomography | 1 | 2014 | 354 | 0.090 |
Why?
|
| Genotype | 1 | 2017 | 1888 | 0.090 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2012 | 139 | 0.090 |
Why?
|
| MART-1 Antigen | 2 | 2003 | 21 | 0.090 |
Why?
|
| Immunoblotting | 1 | 2012 | 274 | 0.090 |
Why?
|
| Immunohistochemistry | 3 | 2012 | 1815 | 0.090 |
Why?
|
| Classification | 1 | 2012 | 60 | 0.090 |
Why?
|
| Eye Neoplasms | 1 | 2012 | 25 | 0.090 |
Why?
|
| Lymphoproliferative Disorders | 1 | 1992 | 105 | 0.090 |
Why?
|
| Transplantation, Homologous | 4 | 2016 | 1026 | 0.090 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2012 | 111 | 0.090 |
Why?
|
| B7-2 Antigen | 5 | 2001 | 42 | 0.090 |
Why?
|
| Interferon-alpha | 2 | 2026 | 191 | 0.090 |
Why?
|
| DNA Primers | 1 | 2012 | 530 | 0.090 |
Why?
|
| Autoantibodies | 2 | 2023 | 286 | 0.090 |
Why?
|
| Disease-Free Survival | 4 | 2019 | 1193 | 0.090 |
Why?
|
| Mice, Inbred C3H | 4 | 2016 | 370 | 0.080 |
Why?
|
| Major Histocompatibility Complex | 3 | 2000 | 88 | 0.080 |
Why?
|
| Point Mutation | 1 | 2012 | 237 | 0.080 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2012 | 78 | 0.080 |
Why?
|
| Spleen | 6 | 2003 | 375 | 0.080 |
Why?
|
| Biological Therapy | 1 | 2011 | 46 | 0.080 |
Why?
|
| Health Resources | 1 | 2011 | 80 | 0.080 |
Why?
|
| Receptors, Interleukin-6 | 2 | 2020 | 19 | 0.080 |
Why?
|
| Receptors, CCR5 | 2 | 2024 | 21 | 0.080 |
Why?
|
| Documentation | 1 | 2011 | 111 | 0.080 |
Why?
|
| MAP Kinase Signaling System | 1 | 2011 | 212 | 0.080 |
Why?
|
| Vaccines, Subunit | 1 | 2010 | 54 | 0.080 |
Why?
|
| Lymphocyte Count | 2 | 2016 | 99 | 0.080 |
Why?
|
| Binding Sites | 1 | 2013 | 1159 | 0.080 |
Why?
|
| Crosses, Genetic | 1 | 2010 | 165 | 0.080 |
Why?
|
| Isoantigens | 2 | 2002 | 74 | 0.080 |
Why?
|
| Kv1.3 Potassium Channel | 1 | 2009 | 13 | 0.080 |
Why?
|
| L-Selectin | 1 | 2009 | 17 | 0.080 |
Why?
|
| Scorpion Venoms | 1 | 2009 | 25 | 0.080 |
Why?
|
| Neurotoxins | 1 | 2009 | 45 | 0.080 |
Why?
|
| Potassium Channel Blockers | 1 | 2009 | 62 | 0.080 |
Why?
|
| Head and Neck Neoplasms | 1 | 2016 | 1088 | 0.080 |
Why?
|
| Anorexia | 1 | 2009 | 26 | 0.070 |
Why?
|
| Protein Kinase C-theta | 1 | 2009 | 16 | 0.070 |
Why?
|
| gp100 Melanoma Antigen | 2 | 2006 | 12 | 0.070 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2009 | 15 | 0.070 |
Why?
|
| Hodgkin Disease | 1 | 2010 | 145 | 0.070 |
Why?
|
| Nausea | 1 | 2009 | 94 | 0.070 |
Why?
|
| Glutamate Carboxypeptidase II | 1 | 2009 | 7 | 0.070 |
Why?
|
| Organoplatinum Compounds | 1 | 2009 | 95 | 0.070 |
Why?
|
| Drug Therapy, Combination | 3 | 2020 | 764 | 0.070 |
Why?
|
| Protein Array Analysis | 1 | 2009 | 53 | 0.070 |
Why?
|
| Immunoprecipitation | 1 | 2009 | 139 | 0.070 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 6 | 1993 | 98 | 0.070 |
Why?
|
| Caspases | 1 | 2009 | 151 | 0.070 |
Why?
|
| Models, Biological | 3 | 2018 | 1807 | 0.070 |
Why?
|
| Bryostatins | 2 | 2006 | 14 | 0.070 |
Why?
|
| Taxoids | 1 | 2009 | 127 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2010 | 79 | 0.070 |
Why?
|
| Enzyme Induction | 2 | 2001 | 83 | 0.070 |
Why?
|
| Internet | 1 | 2011 | 358 | 0.070 |
Why?
|
| Transplantation Immunology | 3 | 2004 | 83 | 0.070 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 2 | 2019 | 61 | 0.070 |
Why?
|
| Purine-Nucleoside Phosphorylase | 2 | 2006 | 21 | 0.070 |
Why?
|
| Immunoglobulins | 2 | 2004 | 123 | 0.070 |
Why?
|
| Rituximab | 2 | 2010 | 135 | 0.070 |
Why?
|
| Diarrhea | 1 | 2009 | 180 | 0.070 |
Why?
|
| Medicare | 2 | 2022 | 467 | 0.070 |
Why?
|
| Fatigue | 1 | 2009 | 187 | 0.070 |
Why?
|
| Multigene Family | 1 | 2009 | 204 | 0.070 |
Why?
|
| Integrins | 1 | 2008 | 81 | 0.070 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 4025 | 0.070 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2010 | 262 | 0.070 |
Why?
|
| Minocycline | 1 | 2008 | 14 | 0.070 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2008 | 35 | 0.070 |
Why?
|
| Diterpenes | 1 | 2008 | 24 | 0.070 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2008 | 28 | 0.070 |
Why?
|
| Patient Selection | 4 | 2016 | 726 | 0.070 |
Why?
|
| Cell Survival | 2 | 2013 | 1014 | 0.070 |
Why?
|
| Dibenzocycloheptenes | 1 | 2007 | 2 | 0.070 |
Why?
|
| NFATC Transcription Factors | 2 | 2006 | 52 | 0.070 |
Why?
|
| Protein Prenylation | 1 | 2007 | 10 | 0.070 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2009 | 196 | 0.060 |
Why?
|
| RNA, Untranslated | 1 | 2007 | 70 | 0.060 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2001 | 212 | 0.060 |
Why?
|
| Mice, Inbred CBA | 4 | 1994 | 51 | 0.060 |
Why?
|
| Ribonuclease, Pancreatic | 1 | 2007 | 24 | 0.060 |
Why?
|
| Programmed Cell Death 1 Ligand 2 Protein | 2 | 2004 | 12 | 0.060 |
Why?
|
| Methionine | 1 | 2007 | 64 | 0.060 |
Why?
|
| Transplantation, Heterologous | 1 | 2008 | 375 | 0.060 |
Why?
|
| Immune Sera | 2 | 2003 | 48 | 0.060 |
Why?
|
| Double-Blind Method | 2 | 2022 | 1782 | 0.060 |
Why?
|
| Ovalbumin | 3 | 2015 | 105 | 0.060 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2007 | 130 | 0.060 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2007 | 153 | 0.060 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 2 | 2005 | 116 | 0.060 |
Why?
|
| Abdominal Neoplasms | 1 | 2006 | 38 | 0.060 |
Why?
|
| Transcription, Genetic | 1 | 2010 | 1133 | 0.060 |
Why?
|
| Severity of Illness Index | 2 | 2022 | 2013 | 0.060 |
Why?
|
| Transplantation Conditioning | 2 | 2005 | 388 | 0.060 |
Why?
|
| Eukaryotic Initiation Factors | 1 | 2005 | 10 | 0.060 |
Why?
|
| Concanavalin A | 3 | 1990 | 46 | 0.060 |
Why?
|
| United States | 4 | 2022 | 8197 | 0.060 |
Why?
|
| Carbon Monoxide | 1 | 2005 | 98 | 0.060 |
Why?
|
| Pyridines | 1 | 2007 | 318 | 0.060 |
Why?
|
| High-Throughput Screening Assays | 2 | 2018 | 65 | 0.050 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2006 | 164 | 0.050 |
Why?
|
| Cell-Free System | 3 | 1989 | 45 | 0.050 |
Why?
|
| Cell Polarity | 1 | 2005 | 122 | 0.050 |
Why?
|
| Ionomycin | 3 | 1996 | 19 | 0.050 |
Why?
|
| Biological Availability | 1 | 2004 | 86 | 0.050 |
Why?
|
| Myeloid Differentiation Factor 88 | 2 | 2014 | 59 | 0.050 |
Why?
|
| Graft vs Host Disease | 2 | 2004 | 379 | 0.050 |
Why?
|
| Interphase | 2 | 2001 | 36 | 0.050 |
Why?
|
| CD4-CD8 Ratio | 1 | 2004 | 18 | 0.050 |
Why?
|
| Cytochalasin D | 1 | 2004 | 15 | 0.050 |
Why?
|
| Statistics, Nonparametric | 1 | 2004 | 302 | 0.050 |
Why?
|
| Plasma Membrane Calcium-Transporting ATPases | 1 | 2004 | 6 | 0.050 |
Why?
|
| Calcium-Transporting ATPases | 1 | 2004 | 27 | 0.050 |
Why?
|
| Glycolysis | 1 | 2005 | 198 | 0.050 |
Why?
|
| Amino Acids | 1 | 2005 | 246 | 0.050 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2004 | 80 | 0.050 |
Why?
|
| Imatinib Mesylate | 2 | 2014 | 128 | 0.050 |
Why?
|
| Ion Transport | 1 | 2004 | 86 | 0.050 |
Why?
|
| PC12 Cells | 1 | 2003 | 112 | 0.050 |
Why?
|
| Adenocarcinoma | 2 | 2009 | 1211 | 0.050 |
Why?
|
| Fas Ligand Protein | 1 | 2003 | 47 | 0.050 |
Why?
|
| bcl-X Protein | 1 | 2003 | 57 | 0.050 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2004 | 71 | 0.050 |
Why?
|
| Cell Membrane | 2 | 2004 | 673 | 0.050 |
Why?
|
| Chemokine CCL19 | 1 | 2003 | 11 | 0.050 |
Why?
|
| Chemokine CCL21 | 1 | 2003 | 16 | 0.050 |
Why?
|
| Receptors, CCR7 | 1 | 2003 | 20 | 0.050 |
Why?
|
| Receptors, Chemokine | 1 | 2003 | 30 | 0.050 |
Why?
|
| Cation Transport Proteins | 1 | 2004 | 65 | 0.050 |
Why?
|
| Chemokines, CC | 1 | 2003 | 36 | 0.050 |
Why?
|
| Oxygen | 1 | 2008 | 802 | 0.050 |
Why?
|
| Remission Induction | 1 | 2025 | 754 | 0.050 |
Why?
|
| Haplotypes | 1 | 2025 | 656 | 0.050 |
Why?
|
| Calcium Signaling | 1 | 2004 | 142 | 0.050 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2022 | 35 | 0.050 |
Why?
|
| Mice, Inbred Strains | 2 | 1995 | 281 | 0.050 |
Why?
|
| Antigens | 1 | 2003 | 225 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2014 | 2585 | 0.050 |
Why?
|
| Cell Cycle Proteins | 1 | 2005 | 419 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2016 | 3272 | 0.050 |
Why?
|
| Angiotensin II | 1 | 2022 | 98 | 0.050 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2022 | 65 | 0.050 |
Why?
|
| Pathologists | 1 | 2022 | 44 | 0.050 |
Why?
|
| Microsatellite Instability | 1 | 2022 | 68 | 0.050 |
Why?
|
| Autoimmunity | 1 | 2004 | 195 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2004 | 3606 | 0.040 |
Why?
|
| Rats | 2 | 2009 | 4071 | 0.040 |
Why?
|
| Histocompatibility Antigen H-2D | 1 | 2001 | 4 | 0.040 |
Why?
|
| Inflammation | 2 | 2020 | 1120 | 0.040 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2021 | 39 | 0.040 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2001 | 98 | 0.040 |
Why?
|
| Infusions, Intravenous | 2 | 2014 | 412 | 0.040 |
Why?
|
| Enterovirus | 1 | 2000 | 16 | 0.040 |
Why?
|
| STAT6 Transcription Factor | 1 | 2000 | 32 | 0.040 |
Why?
|
| Viral Load | 1 | 2021 | 161 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2021 | 166 | 0.040 |
Why?
|
| Guidelines as Topic | 2 | 2011 | 169 | 0.040 |
Why?
|
| Antibodies, Blocking | 1 | 2000 | 22 | 0.040 |
Why?
|
| Gene Transfer Techniques | 1 | 2000 | 155 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2021 | 288 | 0.040 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2000 | 87 | 0.040 |
Why?
|
| Indicators and Reagents | 1 | 2000 | 68 | 0.040 |
Why?
|
| Biotinylation | 1 | 2000 | 43 | 0.040 |
Why?
|
| Biological Products | 1 | 2022 | 189 | 0.040 |
Why?
|
| Interleukin-1 | 2 | 1991 | 72 | 0.040 |
Why?
|
| Paraneoplastic Syndromes | 1 | 1999 | 16 | 0.040 |
Why?
|
| Recurrence | 2 | 2018 | 1254 | 0.040 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2000 | 106 | 0.040 |
Why?
|
| Muscle Fatigue | 1 | 1999 | 23 | 0.040 |
Why?
|
| Contrast Media | 1 | 2004 | 1011 | 0.040 |
Why?
|
| Specific Pathogen-Free Organisms | 2 | 1997 | 85 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2020 | 166 | 0.040 |
Why?
|
| Oncogene Proteins, Viral | 1 | 1999 | 33 | 0.040 |
Why?
|
| Medical Oncology | 2 | 2013 | 421 | 0.040 |
Why?
|
| Incidence | 1 | 2004 | 1779 | 0.040 |
Why?
|
| Tracheostomy | 1 | 1999 | 48 | 0.040 |
Why?
|
| Forecasting | 1 | 2000 | 295 | 0.040 |
Why?
|
| Quantitative Trait Loci | 1 | 2023 | 663 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-fyn | 2 | 1995 | 22 | 0.040 |
Why?
|
| Cell Compartmentation | 1 | 1998 | 69 | 0.040 |
Why?
|
| Papillomavirus Vaccines | 1 | 1999 | 60 | 0.030 |
Why?
|
| Protein Stability | 1 | 2018 | 105 | 0.030 |
Why?
|
| Exosomes | 1 | 2019 | 66 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2022 | 910 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2021 | 523 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2023 | 10973 | 0.030 |
Why?
|
| Systems Biology | 1 | 2018 | 51 | 0.030 |
Why?
|
| Thy-1 Antigens | 2 | 1995 | 17 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2020 | 358 | 0.030 |
Why?
|
| Papillomaviridae | 1 | 1999 | 184 | 0.030 |
Why?
|
| Pleura | 2 | 1972 | 31 | 0.030 |
Why?
|
| Amino Acid Sequence | 4 | 2009 | 2005 | 0.030 |
Why?
|
| Microglia | 1 | 2019 | 131 | 0.030 |
Why?
|
| Sarcoma, Experimental | 1 | 1997 | 53 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2018 | 193 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2019 | 4823 | 0.030 |
Why?
|
| Herpesviridae | 1 | 2017 | 13 | 0.030 |
Why?
|
| Placenta Growth Factor | 1 | 2018 | 85 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2019 | 206 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2009 | 1836 | 0.030 |
Why?
|
| Adolescent | 4 | 2018 | 10080 | 0.030 |
Why?
|
| Acute Disease | 1 | 1999 | 860 | 0.030 |
Why?
|
| Spermatogonia | 1 | 1997 | 12 | 0.030 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 107 | 0.030 |
Why?
|
| Metagenome | 1 | 2018 | 123 | 0.030 |
Why?
|
| MDS1 and EVI1 Complex Locus Protein | 1 | 2016 | 7 | 0.030 |
Why?
|
| Regulatory-Associated Protein of mTOR | 1 | 2016 | 12 | 0.030 |
Why?
|
| Patient Safety | 1 | 2019 | 235 | 0.030 |
Why?
|
| Temperature | 1 | 2018 | 442 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 287 | 0.030 |
Why?
|
| Osteonectin | 1 | 2016 | 22 | 0.030 |
Why?
|
| bcl-Associated Death Protein | 1 | 1996 | 19 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2018 | 479 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 903 | 0.030 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2016 | 75 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2016 | 26 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2016 | 123 | 0.030 |
Why?
|
| Graft Survival | 2 | 2016 | 994 | 0.030 |
Why?
|
| Genes, ras | 1 | 1996 | 97 | 0.030 |
Why?
|
| Immunity, Active | 1 | 1996 | 8 | 0.030 |
Why?
|
| Testis | 1 | 1997 | 150 | 0.030 |
Why?
|
| Lymphangiogenesis | 1 | 2016 | 44 | 0.030 |
Why?
|
| CD47 Antigen | 1 | 2016 | 26 | 0.030 |
Why?
|
| Muromonab-CD3 | 1 | 1996 | 70 | 0.030 |
Why?
|
| Lung | 1 | 2022 | 1407 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2020 | 588 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 1999 | 462 | 0.030 |
Why?
|
| Antibodies, Neoplasm | 1 | 1996 | 87 | 0.030 |
Why?
|
| Morpholines | 1 | 2015 | 67 | 0.030 |
Why?
|
| Heterografts | 1 | 2016 | 121 | 0.030 |
Why?
|
| Protein Kinases | 1 | 1996 | 212 | 0.030 |
Why?
|
| Cell Transplantation | 1 | 1995 | 46 | 0.030 |
Why?
|
| Cycloheximide | 1 | 1995 | 54 | 0.030 |
Why?
|
| Hindlimb | 1 | 1996 | 98 | 0.030 |
Why?
|
| Disease Management | 2 | 2013 | 377 | 0.030 |
Why?
|
| Receptors, CCR2 | 1 | 2015 | 34 | 0.030 |
Why?
|
| Aminopyridines | 1 | 2015 | 56 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2016 | 211 | 0.030 |
Why?
|
| Allografts | 1 | 2016 | 220 | 0.030 |
Why?
|
| Leukocytes | 1 | 2016 | 212 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2018 | 977 | 0.030 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 2 | 1993 | 11 | 0.030 |
Why?
|
| Receptors, Purinergic P2X7 | 1 | 2014 | 10 | 0.030 |
Why?
|
| Interferon Regulatory Factor-3 | 1 | 2014 | 16 | 0.030 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2014 | 25 | 0.030 |
Why?
|
| Histocompatibility Antigens | 2 | 1992 | 37 | 0.030 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2014 | 53 | 0.030 |
Why?
|
| Cloning, Molecular | 1 | 1995 | 581 | 0.030 |
Why?
|
| Radiation, Ionizing | 1 | 2014 | 123 | 0.030 |
Why?
|
| Fluorocarbons | 1 | 2014 | 64 | 0.030 |
Why?
|
| Risk Factors | 2 | 2021 | 6233 | 0.030 |
Why?
|
| Type C Phospholipases | 1 | 1994 | 26 | 0.030 |
Why?
|
| Phosphotyrosine | 1 | 1994 | 31 | 0.030 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2014 | 95 | 0.030 |
Why?
|
| Receptors, Notch | 1 | 2014 | 139 | 0.030 |
Why?
|
| Tyrosine | 1 | 1994 | 135 | 0.020 |
Why?
|
| RNA Interference | 1 | 2014 | 388 | 0.020 |
Why?
|
| Cyclosporins | 2 | 1990 | 56 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2016 | 423 | 0.020 |
Why?
|
| Exons | 1 | 2014 | 451 | 0.020 |
Why?
|
| GTP Phosphohydrolases | 1 | 2013 | 83 | 0.020 |
Why?
|
| Receptors, Lymphocyte Homing | 1 | 1992 | 11 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 564 | 0.020 |
Why?
|
| Citrus paradisi | 1 | 2012 | 5 | 0.020 |
Why?
|
| Protein Biosynthesis | 1 | 1995 | 393 | 0.020 |
Why?
|
| Ketoconazole | 1 | 2012 | 23 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 582 | 0.020 |
Why?
|
| Organ Transplantation | 1 | 2016 | 306 | 0.020 |
Why?
|
| Muscle, Smooth | 1 | 1993 | 299 | 0.020 |
Why?
|
| Pneumothorax | 1 | 1972 | 51 | 0.020 |
Why?
|
| Hyperlipidemias | 1 | 2012 | 92 | 0.020 |
Why?
|
| Access to Information | 1 | 2012 | 30 | 0.020 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 1991 | 45 | 0.020 |
Why?
|
| Colonic Neoplasms | 2 | 2007 | 582 | 0.020 |
Why?
|
| Drainage | 1 | 1972 | 176 | 0.020 |
Why?
|
| International Cooperation | 1 | 2011 | 132 | 0.020 |
Why?
|
| Hyperglycemia | 1 | 2012 | 186 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 1993 | 440 | 0.020 |
Why?
|
| Awards and Prizes | 1 | 2011 | 37 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2014 | 516 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2013 | 480 | 0.020 |
Why?
|
| 8-Bromo Cyclic Adenosine Monophosphate | 1 | 1990 | 13 | 0.020 |
Why?
|
| Cholera Toxin | 1 | 1990 | 21 | 0.020 |
Why?
|
| Phosphatidylinositols | 1 | 1990 | 18 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2010 | 52 | 0.020 |
Why?
|
| Receptors, Fc | 1 | 1990 | 38 | 0.020 |
Why?
|
| Immunologic Techniques | 1 | 1990 | 25 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2013 | 985 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 1990 | 239 | 0.020 |
Why?
|
| Dexamethasone | 1 | 1991 | 318 | 0.020 |
Why?
|
| Biological Assay | 1 | 1990 | 82 | 0.020 |
Why?
|
| Peptide Library | 1 | 2009 | 87 | 0.020 |
Why?
|
| B-Cell CLL-Lymphoma 10 Protein | 1 | 2009 | 8 | 0.020 |
Why?
|
| Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein | 1 | 2009 | 7 | 0.020 |
Why?
|
| Xenopus laevis | 1 | 2009 | 140 | 0.020 |
Why?
|
| Physicians | 1 | 2016 | 685 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2017 | 1850 | 0.020 |
Why?
|
| STAT5 Transcription Factor | 1 | 2009 | 44 | 0.020 |
Why?
|
| Drug Design | 1 | 2009 | 135 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 1991 | 356 | 0.020 |
Why?
|
| Cervical Vertebrae | 1 | 2012 | 251 | 0.020 |
Why?
|
| Oocytes | 1 | 2009 | 213 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2010 | 395 | 0.020 |
Why?
|
| Multiprotein Complexes | 1 | 2009 | 106 | 0.020 |
Why?
|
| Protein Engineering | 1 | 2009 | 159 | 0.020 |
Why?
|
| Quality of Life | 1 | 2016 | 1895 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2012 | 1012 | 0.020 |
Why?
|
| Tumor Necrosis Factor Ligand Superfamily Member 14 | 1 | 2007 | 14 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 1992 | 834 | 0.020 |
Why?
|
| Hematopoiesis | 1 | 1988 | 186 | 0.020 |
Why?
|
| Intestinal Diseases | 1 | 1967 | 84 | 0.020 |
Why?
|
| Intestinal Obstruction | 1 | 1967 | 97 | 0.020 |
Why?
|
| Bone Marrow | 1 | 1988 | 418 | 0.020 |
Why?
|
| Interleukin-23 Subunit p19 | 1 | 2006 | 9 | 0.010 |
Why?
|
| Jurkat Cells | 1 | 2006 | 85 | 0.010 |
Why?
|
| Interleukin-23 | 1 | 2006 | 63 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2009 | 1391 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2006 | 300 | 0.010 |
Why?
|
| Histocompatibility | 1 | 2005 | 71 | 0.010 |
Why?
|
| Siblings | 1 | 2005 | 113 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 2666 | 0.010 |
Why?
|
| Cause of Death | 1 | 2005 | 278 | 0.010 |
Why?
|
| Gadolinium DTPA | 1 | 2004 | 239 | 0.010 |
Why?
|
| CHO Cells | 1 | 2003 | 188 | 0.010 |
Why?
|
| Transplantation Chimera | 1 | 2003 | 84 | 0.010 |
Why?
|
| Lactones | 1 | 2003 | 28 | 0.010 |
Why?
|
| Macrolides | 1 | 2003 | 32 | 0.010 |
Why?
|
| Transgenes | 1 | 2003 | 173 | 0.010 |
Why?
|
| Premedication | 1 | 2003 | 57 | 0.010 |
Why?
|
| Metacarpus | 1 | 1962 | 5 | 0.010 |
Why?
|
| Osteoma, Osteoid | 1 | 1962 | 7 | 0.010 |
Why?
|
| Osteoma | 1 | 1962 | 4 | 0.010 |
Why?
|
| Cricetinae | 1 | 2003 | 533 | 0.010 |
Why?
|
| Integrin alphaXbeta2 | 1 | 2002 | 2 | 0.010 |
Why?
|
| Brain | 1 | 1993 | 2430 | 0.010 |
Why?
|
| Peritoneal Cavity | 1 | 1962 | 19 | 0.010 |
Why?
|
| Chyle | 1 | 1962 | 4 | 0.010 |
Why?
|
| Exudates and Transudates | 1 | 1962 | 13 | 0.010 |
Why?
|
| Chylothorax | 1 | 1962 | 9 | 0.010 |
Why?
|
| Chylous Ascites | 1 | 1962 | 9 | 0.010 |
Why?
|
| Body Fluids | 1 | 1962 | 35 | 0.010 |
Why?
|
| Radiography | 2 | 2001 | 764 | 0.010 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 1 | 2001 | 18 | 0.010 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2002 | 64 | 0.010 |
Why?
|
| Dimerization | 1 | 2001 | 149 | 0.010 |
Why?
|
| Osteochondritis | 1 | 1961 | 2 | 0.010 |
Why?
|
| Mediastinal Neoplasms | 1 | 2001 | 41 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2003 | 483 | 0.010 |
Why?
|
| Mesothelioma | 1 | 2004 | 346 | 0.010 |
Why?
|
| Thoracic Injuries | 1 | 1961 | 42 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2004 | 521 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 2003 | 370 | 0.010 |
Why?
|
| Self Mutilation | 1 | 1979 | 1 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2000 | 126 | 0.010 |
Why?
|
| Parotitis | 1 | 1959 | 6 | 0.010 |
Why?
|
| Syndrome | 1 | 1961 | 438 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 1962 | 316 | 0.010 |
Why?
|
| Enterostomy | 1 | 1959 | 3 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2002 | 801 | 0.010 |
Why?
|
| Colostomy | 1 | 1959 | 14 | 0.010 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 1999 | 30 | 0.010 |
Why?
|
| Foreign Bodies | 1 | 1979 | 61 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 1999 | 153 | 0.010 |
Why?
|
| Parietal Lobe | 1 | 1979 | 114 | 0.010 |
Why?
|
| Anal Canal | 1 | 1959 | 94 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 1998 | 217 | 0.010 |
Why?
|
| Intestines | 1 | 2001 | 441 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2004 | 831 | 0.010 |
Why?
|
| Surgical Procedures, Operative | 1 | 1959 | 224 | 0.010 |
Why?
|
| Cell Lineage | 1 | 1998 | 332 | 0.010 |
Why?
|
| Mandibular Diseases | 1 | 1956 | 17 | 0.010 |
Why?
|
| ras Guanine Nucleotide Exchange Factors | 1 | 1996 | 8 | 0.010 |
Why?
|
| GRB2 Adaptor Protein | 1 | 1996 | 10 | 0.010 |
Why?
|
| Hypertrophy | 1 | 1956 | 66 | 0.010 |
Why?
|
| Guanosine Triphosphate | 1 | 1996 | 36 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 1996 | 68 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 1996 | 77 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1996 | 122 | 0.010 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1996 | 85 | 0.010 |
Why?
|
| Hyperplasia | 1 | 1956 | 148 | 0.010 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 1996 | 76 | 0.010 |
Why?
|
| Disease | 1 | 1956 | 92 | 0.010 |
Why?
|
| Placenta | 1 | 1997 | 203 | 0.010 |
Why?
|
| Mandible | 1 | 1956 | 128 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 1998 | 566 | 0.010 |
Why?
|
| CD2 Antigens | 1 | 1993 | 22 | 0.010 |
Why?
|
| Sex Factors | 1 | 1997 | 1138 | 0.010 |
Why?
|
| CD5 Antigens | 1 | 1992 | 13 | 0.010 |
Why?
|
| Methods | 1 | 1972 | 134 | 0.010 |
Why?
|
| Leukocyte Common Antigens | 1 | 1992 | 50 | 0.010 |
Why?
|
| Cell Adhesion Molecules | 1 | 1993 | 184 | 0.010 |
Why?
|
| Lymphoma, B-Cell | 1 | 1991 | 110 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 1991 | 313 | 0.000 |
Why?
|
| Pregnancy | 1 | 1997 | 3244 | 0.000 |
Why?
|
| Postoperative Complications | 1 | 1959 | 2681 | 0.000 |
Why?
|
| Macrophage-Activating Factors | 1 | 1987 | 2 | 0.000 |
Why?
|
| Extracellular Space | 1 | 1987 | 84 | 0.000 |
Why?
|
| Mice, Inbred A | 1 | 1984 | 21 | 0.000 |
Why?
|
| Binding, Competitive | 1 | 1984 | 136 | 0.000 |
Why?
|
| Formaldehyde | 1 | 1984 | 52 | 0.000 |
Why?
|
| Polymers | 1 | 1984 | 225 | 0.000 |
Why?
|
| Parietal Bone | 1 | 1979 | 16 | 0.000 |
Why?
|
| Needles | 1 | 1979 | 43 | 0.000 |
Why?
|
| Prisoners | 1 | 1979 | 48 | 0.000 |
Why?
|
| Infant | 1 | 1962 | 3328 | 0.000 |
Why?
|